Article
Oncology
Hope S. Rugo, Peter Kabos, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J. Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney
Summary: This study investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The combination therapy demonstrated antitumor activity, but had high rates of ILD/pneumonitis and severe transaminase elevations, which does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.
Article
Oncology
Erik S. Knudsen, Emily Schultz, Deanna Hamilton, Kris Attwood, Stephen Edge, Tracey O'Connor, Ellis Levine, Agnieszka K. Witkiewicz
Summary: This article reports a real-world experience related to the use of CDK4/6 inhibitors for the treatment of metastatic hormone receptor-positive and HER2-negative breast cancer, focusing on clinical and demographic features associated with progression-free survival.
Article
Oncology
K. Nozawa, M. Terada, M. Onishi, Y. Ozaki, T. Takano, W. Fakhouri, D. Novick, J. M. Haro, L. H. Faris, T. Kawaguchi, Y. Tanizawa, Junji Tsurutani
Summary: This study describes the patient characteristics, treatment patterns, and outcomes of female patients with HR+/HER2- metastatic breast cancer who received abemaciclib treatment in routine clinical practice in Japan. The results show that patients with HR+/HER2- MBC in Japan benefit from abemaciclib treatment in terms of treatment response and median progression-free survival, which is consistent with the evidence from clinical trials.
Article
Oncology
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzalez Farre, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R. Osborne, Rashmi K. Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Summary: The DESTINY-Breast01 study evaluated the efficacy of trastuzumab deruxtecan in heavily pretreated HER2-positive metastatic breast cancer patients, and found that it showed durable clinical activity in patients with treated brain metastases.
Article
Medicine, General & Internal
Gebra Cuyun Carter, Kristin M. Sheffield, Anala Gossai, Yu-Jing Huang, Yajun Emily Zhu, Lee Bowman, Emily Nash Smyth, Raina Mathur, Aaron B. Cohen, Erik Rasmussen, Shreya Balakrishna, Claudia Morato Guimaraes, Sarah Rybowski, Andrew D. Seidman
Summary: This retrospective observational study described the baseline characteristics, real-world treatment patterns, and outcomes of patients with metastatic breast cancer treated with abemaciclib in the United States. The study found that patients benefited from abemaciclib treatment in the real world, similar to results seen in clinical trials. More research is needed to further investigate outcomes associated with abemaciclib treatment.
CURRENT MEDICAL RESEARCH AND OPINION
(2021)
Article
Oncology
Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumi, Elena Aguirre, Miguel Angel Segui, Manuel Atienza, Silvia Diaz-Cerezo, Alberto Molero, Jose Manuel Cervera, Joaquin Gavila
Summary: This retrospective study in Spain found that abemaciclib is effective for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. It can be used as monotherapy or in combination with endocrine therapy.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Yingcheng Wang, Mingjun Rui, Xin Guan, Yingdan Cao, Pingyu Chen
Summary: The study evaluated the cost-effectiveness of ABE + FUL compared to PAL + FUL, RIB + FUL, and FUL as second-line treatment for HR+/HER2- advanced or metastatic breast cancer in the US. Results suggest that ABE + FUL may be cost-effective compared to RIB + FUL but not compared to PAL + FUL or FUL.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Masakazu Toi, Chiun-Sheng Huang, Young-Hyuck Im, Joohyuk Sohn, Wei Zhang, Sachi Sakaguchi, Nadine Haddad, Gertjan van Hal, George W. Sledge Jr
Summary: The MONARCH 2 study demonstrates the efficacy of abemaciclib/placebo + fulvestrant in treating hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer, with improved progression-free survival in East Asian patients.
Article
Oncology
Ni Zeng, Jiaqi Han, Zijian Liu, Jinlan He, Kun Tian, Nianyong Chen
Summary: Recently updated clinical studies have shown that CDK4/6 inhibitors, such as Palbo, Ribo, and Abem, in combination with NSAI significantly prolong survival in postmenopausal women with HR+/HER2- ABC. However, the high cost of these inhibitors poses a financial burden. This study compared the effectiveness and cost-effectiveness of CDK4/6 inhibitors in China, and found that Abem + NSAI was cost-effective, while Palbo + NSAI and Ribo + NSAI were only cost-effective if drug prices were substantially reduced.
Article
Oncology
Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo K. Imamura, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka, Kenichi Yoshimura, Toshimi Takano
Summary: This study evaluated the efficacy and safety of the combination of the anti-PD-1 antibody nivolumab and the CDK4/6 inhibitor abemaciclib in hormone receptor-positive breast cancer. The combination therapy was found to be effective but caused severe and prolonged immune-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jennifer J. Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna B. Wedam, Melanie Royce, Danielle Krol, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The combination of cyclin-dependent kinase 4/6 inhibitors (CDKIs) with fulvestrant in breast cancer patients demonstrates consistent overall survival benefit, supporting the existing standard treatment approach.
Review
Oncology
Mark Pegram, Richard Pietras, Chau T. Dang, Rashmi Murthy, Thomas Bachelot, Wolfgang Janni, Priyanka Sharma, Erika Hamilton, Cristina Saura
Summary: Breast cancer with expression of ER and/or PR and overexpression/amplification of HER2 represents a small percentage of all breast cancers in the US. Current treatment for HR+/HER2+ BC includes anti-HER2 monoclonal antibodies plus chemotherapy, but more targeted combinations should be investigated. Dual HR and HER2 pathway targeting is a rational approach to prevent treatment resistance, although limited clinical trial data is available. Attenuating other signaling pathways involved in crosstalk between receptors is also under investigation. Combined receptor blockade targeting HER2 and ER has scientific and clinical rationale for advanced-stage HR+/HER2+ disease.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Masakazu Toi, Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Joohyuk Sohn, In Hae Park, Seock-Ah Im, Shin-Cheh Chen, Sotaro Enatsu, P. Kellie Turner, Valerie A. M. Andre, Molly C. Hardebeck, Sachi Sakaguchi, Matthew P. Goetz, George W. Sledge
Summary: In East Asian patients with HR+, HER2- advanced breast cancer, abemaciclib in combination with ET demonstrated significantly prolonged progression-free survival, with generally tolerable safety profiles. Pharmacokinetics were similar between East Asians and non-East Asians in both MONARCH 2 and MONARCH 3 trials.
Review
Oncology
E. Stavrou, E. P. Winer, N. U. Lin
Summary: The overexpression of the HER2/neu receptor in breast cancer is associated with an increased risk of brain metastases, especially in advanced cases. Management of HER2-positive brain metastases often involves surgery, radiation, and systemic therapies by an experienced multidisciplinary team, and poses unique clinical challenges in prevention and treatment.
